HOW I APPROACH
How I approach B-lymphoblastic lymphoma in children
Kaitlin J. Devine,
Carol Fries,
Michelle Hermiston,
Birte Wistinghausen,
Corresponding Author
Kaitlin J. Devine
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Correspondence
Kaitlin J. Devine, Division of Oncology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, USA.
Email: [email protected]
Search for more papers by this authorCarol Fries
Department of Pediatrics, Division of Hematology/Oncology, University of Rochester, Rochester, New York, USA
Search for more papers by this authorMichelle Hermiston
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorBirte Wistinghausen
Division of Oncology, Center for Cancer and Blood Disorders, Children's National Hospital, Washington, District of Columbia, USA
Search for more papers by this authorKaitlin J. Devine,
Carol Fries,
Michelle Hermiston,
Birte Wistinghausen,
Corresponding Author
Kaitlin J. Devine
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Correspondence
Kaitlin J. Devine, Division of Oncology, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, USA.
Email: [email protected]
Search for more papers by this authorCarol Fries
Department of Pediatrics, Division of Hematology/Oncology, University of Rochester, Rochester, New York, USA
Search for more papers by this authorMichelle Hermiston
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California San Francisco, San Francisco, California, USA
Search for more papers by this authorBirte Wistinghausen
Division of Oncology, Center for Cancer and Blood Disorders, Children's National Hospital, Washington, District of Columbia, USA
Search for more papers by this authorKaitlin J. Devine and Carol Fries contributed equally as co-first authors.
Abstract
There are limited data pertaining to the prognostic features and optimal therapeutic approach for the 20%–25% of children with lymphoblastic lymphoma (LLy) who have the B-lymphoblastic subtype. Outcomes are favorable following treatment modeled after acute lymphoblastic leukemia (ALL) regimens, but prognosis is dismal after relapse, and there are no established features for predicting therapy response. Ongoing US and international trials will include the largest cohort of uniformly treated patients with B-LLy to date, providing an opportunity to define clinical and molecular predictors of relapse and to establish a standard of care for treatment to improve outcomes for this rare pediatric cancer.
CONFLICT OF INTEREST STATEMENT
The authors declare they have no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Kroeze E, Arias Padilla L, Bakker M, et al. Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement. Cancers (Basel). 2022; 14(16): 3895. doi:10.3390/cancers14163895
- 2Meyer JA, Zhou D, Mason CC, et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017; 64(7):e26363. doi:10.1002/pbc.26363
- 3Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group. Br J Haematol. 2013; 162(6): 792-801. doi:10.1111/bjh.12460
- 4Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011; 152(4): 441-451. doi:10.1111/j.1365-2141.2010.08541.x
- 5 Special section: cancer in children and adolescents. In: American Cancer Society: Cancer Facts and Figures 2014. Atlanta GACS; American Cancer Society; 2014: 25-42.
- 6Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2): 83-103. doi:10.3322/caac.21219
- 7Termuhlen AM, Smith LM, Perkins SL, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012; 59(7): 1229-1233. doi:10.1002/pbc.24149
- 8Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013; 30(6): 484-508. doi:10.3109/08880018.2013.789574
- 9Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12): 2142-2150. doi:10.1038/leu.2008.251
- 10Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112): 2569-2582. doi:10.1016/s0140-6736(17)31610-0
- 11Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131(1): 39-49. doi:10.1111/j.1365-2141.2005.05735.x
- 12Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7(3): 332-339.
- 13Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015; 33(18): 2112-2118. doi:10.1200/jco.2014.59.7203
- 14Carraro E, Mussolin L, Onofrillo D, et al. The revised International Paediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS): a test of applicability. Br J Haematol. 2019; 186(6): e201-e203. doi:10.1111/bjh.16079
- 15Sandlund JT, Guillerman RP, Perkins SL, et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol. 2015; 33(18): 2106-2111. doi:10.1200/jco.2014.59.0745
- 16Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12): 5477-5485. doi:10.1182/blood-2008-01-132837
- 17Lovisa F, Gallingani I, Varotto E, et al. Prognostic role of minimal disseminated disease and NOTCH1/FBXW7 mutational status in children with lymphoblastic lymphoma: the AIEOP experience. Diagnostics (Basel). 2021; 11(9): 1594. doi:10.3390/diagnostics11091594
- 18Mussolin L, Buldini B, Lovisa F, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience. Pediatr Blood Cancer. 2015; 62(11): 1906-1913. doi:10.1002/pbc.25607
- 19Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022; 36(7): 1720-1748. doi:10.1038/s41375-022-01620-2
- 20Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000; 35(1): 20-27. doi:10.1002/1096-911x(200007)35:1<20::aid-mpo4>3.0.co;2-l
- 21Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021; 10(9): 1926. doi:10.3390/jcm10091926
- 22Knez V, Bao L, Carstens B, Liang X. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020; 61(9): 2129-2135. doi:10.1080/10428194.2020.1761970
- 23Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage–a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995; 13(2): 359-372. doi:10.1200/jco.1995.13.2.359
- 24Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin's lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979; 44(6): 1990-1999. doi:10.1002/1097-0142(197912)44:6<1990::aid-cncr2820440605>3.0.co;2-9
10.1002/1097-0142(197912)44:6<1990::AID-CNCR2820440605>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 25Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol. 1993; 11(6): 1024-1032. doi:10.1200/jco.1993.11.6.1024
- 26Mora J, Filippa DA, Qin J, Wollner N. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer. 2003; 98(6): 1283-1291. doi:10.1002/cncr.11615
- 27Wollner N, Burchenal JH, Lieberman PH, Exelby P, D'Angio G, Murphy ML. Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976; 37(1): 123-134. doi:10.1002/1097-0142(197601)37:1<123::aid-cncr2820370119>3.0.co;2-7
10.1002/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 28Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med. 1983; 308(10): 559-565. doi:10.1056/nejm198303103081003
- 29Song H, Todd P, Chiarle R, Billett AL, Gellis S. Primary cutaneous B-cell lymphoblastic lymphoma arising from a long-standing lesion in a child and review of the literature. Pediatr Dermatol. 2017; 34(4): e182-e186. doi:10.1111/pde.13169
- 30Muljono A, Graf NS, Arbuckle S. Primary cutaneous lymphoblastic lymphoma in children: series of eight cases with review of the literature. Pathology (Phila). 2009; 41(3): 223-228. doi:10.1080/00313020902756246
10.1080/00313020902756246 Google Scholar
- 31Boccara O, Laloum-Grynberg E, Jeudy G, et al. Cutaneous B-cell lymphoblastic lymphoma in children: a rare diagnosis. J Am Acad Dermatol. 2012; 66(1): 51-57. doi:10.1016/j.jaad.2010.10.040
- 32Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group report. J Clin Oncol. 2007; 25(25): 3915-3922. doi:10.1200/jco.2007.11.0700
- 33Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006; 24(3): 491-499. doi:10.1200/jco.2005.02.2707
- 34Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017; 102(12): 2086-2096. doi:10.3324/haematol.2015.139162
- 35Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004; 10(6): 293-310. doi:10.1097/01.nrl.0000144287.35993.96
- 36Michaux K, Bergeron C, Gandemer V, Mechinaud F, Uyttebroeck A, Bertrand Y. Relapsed or refractory lymphoblastic lymphoma in children: results and analysis of 23 patients in the EORTC 58951 and the LMT96 protocols. Pediatr Blood Cancer. 2016; 63(7): 1214-1221. doi:10.1002/pbc.25990
- 37Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster Group. J Clin Oncol. 2009; 27(20): 3363-3369. doi:10.1200/jco.2008.19.3367
- 38Burkhardt B, Taj M, Garnier N, et al. Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers (Basel). 2021; 13(9): 2075. doi:10.3390/cancers13092075
- 39Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439-448. doi:10.1056/NEJMoa1709866
- 40Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021; 68(1):e28718. doi:10.1002/pbc.28718
- 41Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020; 136(16): 1803-1812. doi:10.1182/blood.2019004043
- 42Nguyen HTK, Terao MA, Green DM, Pui CH, Inaba H. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management. Cancer. 2021; 127(17): 3067-3081. doi:10.1002/cncr.33609
- 43Hagedorn N, Acquaviva C, Fronkova E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood. 2007; 110(12): 4022-4029. doi:10.1182/blood-2007-04-082040
- 44Barredo JC, Hastings C, Lu X, et al. Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: a Children's Oncology Group study. Pediatr Blood Cancer. 2018; 65(5):e26928. doi:10.1002/pbc.26928
- 45Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012; 120(14): 2807-2816. doi:10.1182/blood-2012-02-265884
- 46Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2018; 16(10): 664-666.
- 47von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016; 34(36): 4381-4389. doi:10.1200/jco.2016.67.3301
